Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04310241 · ClinicalTrials.gov registry record
Visual Function Abnormalities in Strabismus and Amblyopia and Response to Therapy
A clinical trial of Amblyopia and Strabismus, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT04310241: Recruiting study of Amblyopia and Strabismus, sponsored by The Cleveland Clinic.
NCT04310241 is a study of Amblyopia and Strabismus that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 150 participants, roughly in line with the 159-participant average among 24 other Amblyopia trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04310241, a study of Amblyopia and Strabismus, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Amblyopia and strabismus are characterized by a reduction in visual acuity, contrast sensitivity, grating acuity, vernier acuity, reading difficulties and binocular visual function deficits. Treated patients have residual visual function deficits. The purpose of the current study is to quantify various visual functions in amblyopic and strabismic participants at baseline, during and at the completion of treatment.
Primary Outcome
contrast sensitivity
Conditions Studied
Interventions
- BEHAVIORAL Patching therapy, Glasses
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-02-21 |
| Est. Completion | 2027-03-12 |
What NCT04310241 shows while recruiting
NCT04310241 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 159-participant average among 24 other Amblyopia trials with a reported enrollment target.
The record links to 2 conditions, with Amblyopia appearing as the primary indexed condition, and to 1 intervention - of which Patching therapy, Glasses is the first listed.
NCT04310241 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04310241 about?
NCT04310241 is a clinical study titled "Visual Function Abnormalities in Strabismus and Amblyopia and Response to Therapy". Amblyopia and strabismus are characterized by a reduction in visual acuity, contrast sensitivity, grating acuity, vernier acuity, reading difficulties and binocular visual function deficits. Treated patients have residual visual function deficits. The purpose of the current study is to quantify vari...
What is the current status of trial NCT04310241?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2020-02-21. Estimated completion is 2027-03-12.
What conditions does trial NCT04310241 study?
This clinical trial studies the following conditions: Amblyopia, Strabismus.
What interventions are being tested in trial NCT04310241?
The interventions under investigation include: Patching therapy, Glasses (BEHAVIORAL).
Who is sponsoring clinical trial NCT04310241?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04310241 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amblyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04310241's enrollment target sits among peer trials
150 11th of 24 higher than 14 of 24 other Amblyopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amblyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Noninvasive Brain Stimulation in Adult Amblyopia
RECRUITING · NA
-
OCT Eccentric Fixation and Amblyopia in Children
RECRUITING · NA
-
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
RECRUITING · Phase 3
-
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
RECRUITING · Phase 3
-
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
RECRUITING · Phase 3
-
Clinical Data Registry of Amblyopia Patients on Luminopia Treatment
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI